This report was our free report of the day on a previous date — it has since expired.
Today's free report is available: CNXC 10-Q — Concentrix swings to $988M loss on $1.05B goodwill impairment; revenue slips 1.2%
Get notified when INBP files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsRed Flags Detected
- Covenant Violation (new) — The company did not meet its fixed charge coverage ratio of 1.10 to 1.0 and has requested a waiver from PNC, indicating financial stress.
- Auditor Change (unchanged) — Auditor changed from Marcum to CBIZ; the change appears routine with no disagreements or reportable events disclosed.
Integrated BioPharma swings to -$2.8M net loss as sales fall 19.3% and margins compress
Filed September 25, 2026 · Period ending June 30, 2026 · Compared to 10-K Sep 23, 2025 · ~1 min read
Key Changes
-
high
Net sales fell 19.3% to $43.9M, swinging to a $2.8M net loss ($0.09 diluted EPS) from a $0.8M profit a year earlier.
MD&A verify on EDGAR → -
high
Operating income swung from a $2.0M profit to a $2.7M loss, a $4.7M deterioration, as gross margin collapsed from 10.2% to 1.8%.
MD&A verify on EDGAR → -
high
Customer concentration rose to 90% of consolidated net sales from two customers (Life Extension and Herbalife), up from 84% last year.
Risk Factors verify on EDGAR →
2 more material changes behind this preview — plus the full narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.
Partner
Trade INBP commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Sep 25, 2026 · How we verify